Crohn's disease

• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 "Immune system diseases"
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 "Moderately to Severely Active Crohn’s Disease"
• A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indicat … Pending
  2025-522362-78-00 6 "severely active ulcerative colitis (US) and CD (Crohn’s dise"
• A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co … Pending
  2025-522511-42-00 4
• Methotrexate in paediatric and adolescent Crohn’s disease: an observational study Pending
  2025-524129-42-00 6 "Crohn’s disease"
• A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting
  2025-522001-38-00 4 2026-05-27 "Crohn’s Disease"
• Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting
  2023-508804-39-00 5 2025-10-15 "Ulcerative Colitis or Crohn’s Disease"
• A study to investigate efficacy and safety of brivekimig in participants with Crohn’s disease Recruiting
  2024-517016-30-00 4 2025-09-26 "Crohn’s disease"
• Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting
  2023-503188-40-00 5 2025-01-06 "Active Ulcerative Colitis or Crohn’s Disease"
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2022-502050-14-00 5 2024-06-04 "Crohn's disease"
• A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c … Recruiting
  2023-504265-23-00 4 2023-10-23
• Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohn’s Disease : EMINENT CD Recruiting
  2025-521889-95-00 6 2026-05-04 "Crohn's Disease"
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 "Immune system disseases"
• Tolerance of local administration of cryopreserved autologous stromal vascular fraction combined with micrograft for the treatment of refrac … Recruiting
  2024-519740-32-00 4 2025-12-29
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 "Moderately to Severely Active Crohn's Disease"
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting
  2024-518914-18-00 4 2025-08-27 "Moderate to Severely Active Ulcerative Colitis & Moderate to"
• SIMBA Recruiting
  2024-514740-82-00 6 2025-07-16 "Inflammatory Bowel Disease"
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 "Chron's Disease"
• Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING … Recruiting
  2023-506626-37-00 4 2025-04-18
• A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting
  2024-512633-32-00 4 2025-04-07
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27
• EEN-RICH study Recruiting
  2022-503027-10-00 9 2025-01-21
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 "Moderate to Severe Crohn’s Disease"
• A Long-term Extension Study of Guselkumab in Pediatric Participants Recruiting
  2023-509560-16-00 5 2024-10-29 "Juvenile psoriatic arthritis (jPsA)"

Showing 1–24 of 62 trials